Roche's Ambitious Leap into the Obesity Drug Market

Swiss drugmaker Roche is advancing its experimental obesity drug CT-388 to a phase III trial, aiming to compete with industry leaders Eli Lilly and Novo Nordisk. Roche aims to secure a significant market share in the $150 billion obesity drug industry by 2030, driven by promising results and strategic market understanding.

Swiss pharmaceutical giant Roche has announced its entry into the competitive weight-loss market, signaling its intent to challenge frontrunners Eli Lilly and Novo Nordisk. The company has commenced a phase III trial for its experimental obesity drug, CT-388.

This strategic move follows Roche's acquisition of U.S. biotech firm Carmot Therapeutics, marking a significant effort to gain a foothold in the burgeoning obesity drug market. Analysts predict the industry could reach a valuation of $150 billion annually by the early 2030s.

Roche's pharmaceutical division head, Teresa Graham, stated that the company aims to launch several competitive products by 2030, aspiring to become a leading player in the obesity drug sector. Roche's robust pipeline includes six drug candidates, with hopes that three of these could achieve blockbuster status.

(With inputs from agencies.)